[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, CA Cancer J. Clin. 70 (2020) 7-30. https://doi.org/10.3322/caac.21590.
[2] L. Kuroki, S.R. Guntupalli. Treatment of epithelial ovarian cancer. BMJ 371 (2020) m3773. https://doi.org/10.1136/bmj.m3773. PMID: 33168565.
[3] D.S. Tan, R. Agarwal, S.B. Kaye, Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7 (2006) 925-934. https://doi.org/10.1016/S1470-2045(06)70939-1.
[4] M. Kleppe, T. Wang, T. Van Gorp, B.F. Slangen, A.J. Kruse, R.F. Kruitwagen, Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol. Oncol. 123 (2011) 610-614. https://doi.org/10.1016/j.ygyno.2011.09.013.
[5] M. Kleppe, A.C. Kraima, R.F. Kruitwagen, T. Van Gorp, N.N. Smit, J.C. van Munsteren, M.C. DeRuiter, Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. Int. J. Gynecol. Cancer 25 (2015) 1405-1414. https://doi.org/10.1097/IGC.0000000000000514.
[6] M. Kleppe, B. Brans, T. Van Gorp, B.F.M. Slangen, A.J. Kruse, I.N.A. Pooters, M.G. Lotz, K.K. Van de Vijver, R.F. Kruitwagen. The detection of sentinel nodes in ovarian cancer: a feasibility study. J. Nucl. Med. 55 (2014) 1799-1804. https://doi.org/10.2967/jnumed.114.144329.
[7] D.K. Armstrong, R.D. Alvarez, J.N. Bakkum-Gamez, L. Barroilhet, K. Behbakht, A. Berchuck, L.M. Chen, M. Cristea, M. DeRosa, E.L. Eisenhauer, D.M. Gershenson, H.J. Gray, R. Grisham, A. Hakam, A. Jain, A. Karam, G.E. Konecny, C.A. Leath, J. Liu, H. Mahdi, L. Martin, D. Matei, M. McHale, K. McLean, D.S. Miller, D.M. O'Malley, S. Percac-Lima, E. Ratner, S.W. Remmenga, R. Vargas, T.L. Werner, E. Zsiros, J.L. Burns, A.M. Engh. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 19(2021) 191-226. https://doi.org/10.6004/jnccn.2021.0007. PMID: 33545690.
[8] I.A. Fennimore, N.L. Simon, G. Bills, V.L. Dryfhout, A.M. Schniederjan. Extension of ovarian tissue into the infundibulopelvic ligament beyond visual margins. Gynecol. Oncol. 114 (2009) 61-63. https://doi.org/10.1016/j.ygyno.2009.03.006.
[9] H. Azaïs, A.S. Vignion-Dewalle, M. Carrier, J. Augustin, E. Da Maïa, A. Penel, J. Belghiti, M. Nikpayam, C. Gonthier, L. Ziane, S. Mordon, P. Collinet, G. Canlorbe, C. Uzan. Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer. J Clin Med. 10(2020) 41. https://doi.org/10.3390/jcm10010041. PMID: 33375564; PMCID: PMC7795826.
[10] A.A. Wright, K. Bohlke, D.K. Armstrong, M.A. Bookman, W.A. Cliby, R.L. Coleman, D.S. Dizon, J.J. Kash, L.A. Meyer, K.N. Moore, A.B. Olawaiye, J. Oldham, R. Salani, D. Sparacio, W.P. Tew, I. Vergote, M.I. Edelson. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 34 (2016) 3460-3473. https://doi.org/10.1200/JCO.2016.68.6907.